Grasustek (pegfilgrastim biosimilar) / USV Biologics - LARVOL DELTA

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1 | N=46 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jul 2026 ➔ Jul 2027

Trial completion date • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

UPMC expert discusses price variation for biosimilars (AJMC) - "Brufsky admits that finding this out was an eye-opener for him. 'It's a very complicated process for the pharmacy, the pharmacy and therapeutics committee, and the financial team to figure out exactly what the benefits of a biosimilar are financially. It really depends on a lot of factors that you ordinarily wouldn't have thought of.'...The goal for many in the health-care system is to figure out what the biosimilar threshold is that represents the perfect balance of cost savings and convenience, he said."

Media quote